Clinical Research Directory
Browse clinical research sites, groups, and studies.
H. Pylori Screen-and-treat Study in a Population of Young Adults
Sponsor: University of Latvia
Summary
Gastric cancer remains a major challenge to public health on a global scale. H. pylori related cancer burden contributes to the largest proportion of cancer cases attributable to infections in Europe. Considering its absolute burden and persisting disparities, in addition to the substantial prevalence of H. pylori infection worldwide that is treatable, gastric cancer is a logical target for urgent action for prevention. Population-based H. pylori test-and-treat has therefore been proposed as a strategy for gastric cancer prevention. To fill the gaps in knowledge about gastric cancer prevention through H. pylori screening and eradication in younger adults, a study of a population-based H. pylori test-and-treat strategy in Ireland, Croatia, Latvia, Poland, Romania and Slovenia. Main goals of this study are to assess future program processes, feasibility, acceptability and effectiveness. In total of 6,800 adults aged 30-34 will be tested for H. pylori infection. They will be randomly selected to represent the chosen population and invited to participate in the study based on informed consent. Confirmed infections will be treated by available combined therapy in line with treatment guidelines and the success of eradication will be retested during a control check-up. Patients who will provide their consent to participate will undertake an interview about the risk factors in early childhood and their habits regarding alcohol consumption and use of tobacco. Compliance to testing and treatment, treatment results, adverse effects and reasons for dropping out will be additionally monitored. Gathered data will be analysed in alignment with our research questions. The investigators will disseminate reports and present the results to both the general public and the scientific community in order to foster future developments in gastric cancer prevention.
Official title: Multicentric Transnational H. Pylori Screen-and-treat Study in a Population of Young Adults
Key Details
Gender
All
Age Range
30 Years - 34 Years
Study Type
OBSERVATIONAL
Enrollment
6800
Start Date
2024-03-04
Completion Date
2026-12-01
Last Updated
2024-03-05
Healthy Volunteers
Yes
Interventions
Bismuth-based quadruple therapy
Participants who are positive with H. pylori will receive bismuth-based quadruple therapy: Antibiotic 1 - Amoxicillin 4 x 500 mg or Clarithromycin 2 x 400 mg, Antibiotic 2 - Metronidazole 4 x 400 mg, Proton pump inhibitor - Esomeprazole 2 x 40 mg, Colloidal bismuth - Bismuth oxide 4 x 120 mg.
Levofloxacin-based quadruple therapy
In case there will be a treatment failure after Protocol I is completed, the remaining patients with a positive infection will be referred to a secondary treatment: Antibiotic 1 - Levofloxacin 1 x 500 mg, Antibiotic 2 - Metronidazole 4 x 400 mg, Proton pump inhibitor - Esomeprazole 2 x 40 mg, Colloidal bismuth - Bismuth oxide 4 x 120 mg.
Standard triple therapy
Participants who are positive for H. pylori will receive a standard triple therapy: Antibiotic 1 - Amoxicillin 2 x 1000 mg, Antibiotic 2 - Clarithromycin 2 x 500 mg, Proton pump inhibitor - Esomeprazole 2 x 40 mg.
Levofloxacin-based triple
Participants with treatment failure will be recommended second line treatment - levofloxacin-based: Antibiotic 1 - Levofloxacin 2 x 500 mg, Antibiotic 2 - Amoxicillin 2 x 1000 mg, Proton pump inhibitor - Esomeprazole 2 x 40 mg
Locations (7)
University Hospital Centre Zagreb
Zagreb, City of Zagreb, Croatia
Clinical Hospital Center Rijeka
Rijeka, Croatia
Beacon Hospital
Dublin, Ireland
Clinical and Preventive Medicine of the University of Latvia
Riga, Latvia
Wroclaw Medical University
Wroclaw, Poland
Iuliu Hatieganu University of Medicine and Pharmacy
Cluj-Napoca, Cluj, Romania
National Institute of Public Health, Slovenia
Ljubljana, Slovenia